Ask a pharmaceutical executive what their drug costs, and the answer you receive will depend on what the executive wants you to know. The WAC is public. The AWP is published. The ASP is reported to CMS. But the net price — the manufacturer’s actual revenue per unit after subtracting rebates, discounts, chargebacks, and fees across all market segments — is treated as proprietary intelligence. It is the most economically meaningful drug pricing metric in the United States, and it is the one that virtually no manufacturer voluntarily discloses.
The secrecy is strategic. Net price reveals the true economics of a drug’s commercial position — the margin structure, the competitive concessions, the channel-specific discounting, the rebate obligations to government programs. A competitor with access to another manufacturer’s net prices could calibrate their own contracting strategy with surgical precision. A payer with access to a manufacturer’s net prices across all accounts could benchmark their own contract terms against the market and demand concessions that match the best available deal. A regulator with access to net prices could evaluate whether pricing decisions serve the public interest or merely the manufacturer’s shareholders.
The confidentiality is not absolute. Net revenue — the aggregate output of net pricing across all units sold — appears in public financial filings. For companies with single-product portfolios or strong-selling lead assets, dividing net revenue by estimated unit volume produces a rough approximation of net price per unit. SSR Health has built an entire business on performing this calculation systematically across the branded pharmaceutical market, using financial disclosures, prescription volume data, and proprietary models to estimate product-level net prices. The estimates are widely used, generally respected, and acknowledged by their producer to carry meaningful uncertainty for certain product types.
The gross-to-net waterfall — the cascade of deductions that transforms WAC into net price — is itself a complex accounting exercise. For a typical branded drug, the waterfall includes Medicaid rebates (basic and inflationary), commercial rebates to PBMs, chargebacks from 340B covered entities, prompt-pay discounts to wholesalers, distribution service fees, patient assistance program costs, co-pay card expenses, and various smaller concessions. Each component varies by channel, by payer, by quarter, and by the specific terms of contracts that may span years. The net price that emerges is not a single number but a weighted average across segments, each carrying different GTN characteristics.
The segment variation is significant. A drug’s net price in the Medicaid channel — after basic and inflationary rebates that can exceed one hundred percent of AMP for some products — may be dramatically lower than its net price in the commercial channel, where rebates are negotiated rather than statutory. The 340B channel carries its own pricing, with acquisition costs capped at the ceiling price. Medicare Part D carries rebates negotiated between the manufacturer and Part D plans, supplemented by the IRA’s inflationary rebate requirements. The “net price” reported as a single figure in financial disclosures is an average of these segment-specific net prices, weighted by channel mix. A shift in channel mix — more Medicaid utilization, less commercial — can change the aggregate net price even if no individual contract term changes.
The opacity serves multiple stakeholders. Manufacturers retain negotiating leverage by preventing payers from comparing offers across accounts. PBMs benefit from information asymmetry that allows them to capture spread between what they charge plan sponsors and what they pay manufacturers. Government programs operate under statutory formulas (AMP for Medicaid, ASP for Part B) that provide some visibility but do not capture the full net price including all commercial concessions. Patients bear the most direct cost of opacity — their cost-sharing is frequently calculated on WAC or AWP, not net price, meaning they pay a share of a number that nobody else pays.
The argument for mandatory net price disclosure is conceptually straightforward: if the public is going to debate drug pricing policy, evaluate pharmaceutical profitability, or make coverage decisions that affect millions of patients, that debate should be informed by the actual prices paid rather than published fiction. The argument against is that disclosure would restructure competitive dynamics — potentially eliminating the rebate-driven contracting model entirely — with consequences that are difficult to predict and potentially adverse for some stakeholders, including payers who currently negotiate favorable rebates that they prefer competitors not know about.
The IRA does not mandate net price disclosure, but the Maximum Fair Price program introduces a quasi-public net price for selected drugs. The MFP, while not identical to net price — it is a ceiling rather than an actual transaction price — establishes a publicly known upper bound on what Medicare pays for specific products. Over time, as additional drugs are selected for negotiation, MFP may provide a growing body of reference points against which other prices can be compared, even if net prices themselves remain confidential.
The pharmaceutical industry’s internal culture around net pricing reflects its strategic importance. GTN forecasting teams operate under strict access controls. Contract terms are compartmentalized. Even within a manufacturer, the number of people who can see the complete net price picture across all segments is limited. The information is not merely confidential in the legal sense — it is treated with the operational security of a trade secret, because in many respects that is exactly what it is.
The result is a pharmaceutical market in which the most discussed metric — WAC, the list price — is the least informative, and the most informative metric — net price — is the least discussed. The public debate about drug pricing occurs at the surface level, using numbers that everyone knows are misleading, while the actual economics unfold in private, in contracts that are never disclosed, producing outcomes that can only be estimated from the outside. This is not a temporary informational gap. It is a designed feature of a market in which information asymmetry is a competitive asset. The number nobody publishes is the number that matters most. It stays unpublished for precisely that reason.
